Stock OPTN OPTINOSE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings OptiNose, Inc.

Equities

OPTN

US68404V1008

Real-time Estimate Cboe BZX
Other stock markets
 12:16:38 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.857 USD -5.30% Intraday chart for OptiNose, Inc. -4.66% -33.91%
Apr. 25 Transcript : OptiNose, Inc. - Special Call
Apr. 25 OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
OPTINOSE, INC. Stock OptiNose, Inc.
-36.06% 102M
D+
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.99% 653B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.30% 556B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.47% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.54% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.00% 296B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+12.47% 233B
B+
NOVARTIS AG Stock Novartis AG
+5.49% 201B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.65% 193B
A+
AMGEN INC. Stock Amgen Inc.
-5.99% 144B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. OPTN Stock
  4. Ratings OptiNose, Inc.